IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval

Stock News

03/09

IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.

The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.

The group holds the global intellectual property rights and commercialization rights for IMM0306S.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126203337"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126203337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126203337?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 13:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126203337","market":"other","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.</p>\n<p>The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.</p>\n<p>The group holds the global intellectual property rights and commercialization rights for IMM0306S.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-09 13:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.</p>\n<p>The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.</p>\n<p>The group holds the global intellectual property rights and commercialization rights for IMM0306S.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1126203337","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126203337","pubTimestamp":1773035775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million. The increase follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard"},"translate_title":"IMMUNEONCO-B(01541)延续涨势，IMM0306S临床试验获批后飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01541":1},"content_text":"IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.\nThe increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.\nThe group holds the global intellectual property rights and commercialization rights for IMM0306S.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}